MEI Pharma Inc. (NASDAQ: MEIP)
$2.90
+0.0900 ( +3.20% ) 0.5K
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Market Data
Open
$2.90
Previous close
$2.81
Volume
0.5K
Market cap
$18.82M
Day range
$2.82 - $3.01
52 week range
$2.73 - $7.87
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4/a | Other | 1 | Jan 12, 2024 |
4/a | Other | 1 | Jan 12, 2024 |
8-k | 8K-related | 13 | Dec 26, 2023 |
8-k | 8K-related | 13 | Dec 22, 2023 |
4 | Insider transactions | 1 | Dec 20, 2023 |
4 | Insider transactions | 1 | Dec 20, 2023 |
8-k | 8K-related | 12 | Dec 18, 2023 |
8-k | 8K-related | 17 | Dec 11, 2023 |
3 | Insider transactions | 2 | Nov 14, 2023 |
10-q | Quarterly Reports | 72 | Nov 09, 2023 |